This study aims to determine the normal distribution of desmosine in a healthy population and a population of patients with COPD (ranging from GOLD I-IV). In addition, the inter-day variation and the correlation with 24-hour urinary desmosine will…
ID
Source
Brief title
Condition
- Bronchial disorders (excl neoplasms)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Normal serum desmosine (DES) ug / L for healthy subjects and patients with
COPD
- Inter-day variation DES
- Correlatie with 24-hour urine DES/ serum DES
Secondary outcome
Difference between healthy smokers and healthy non-smokers
Subgroup analysis GOLD I-IV COPD
Background summary
Lung function tests has long been an important pillar in lungdisease. Not only
is lung function used for diagnostic purpose, but also for estimating the
prognosis and evaluating the effect of a specific treatment.
These parameters are far from perfect. They are not always specific or
sensitive, and often measure the outcome of a process and not the process
itself, namely the development of lung injury.
A search for new parameters hasn't yet yielded a good alternatives. There is a
need to develop alternative markers such as bio-markers. Desmosine isodesmosine
and are examples of this.
In many lung diseases, the underlying problem is the destruction of alveolar
tissue and loss of elasticity. The most common diseases are COPD and pulmonary
emphysema. Elastin in the lung is formed by cross linking tropo-elastin
(elastin precursor). This process is possible due to (Iso)desmosine. These
proteins are exclusively found in elastin. In patients with COPD / emphysema
the degradation of elastin stands centrally. This proces happens under the
influence of proteases. These proteins are produced by several inflammatory
cells (macrophages / neutrophils / T cells). Secondly, there is a
downregulation of the anti-proteases, whitch have a protective role on the
pulmonary elastin. The overall result is elastin degradation whitch causes
various components in the bloodstream. These includes the (iso) desmosine.
Because lung tissue consist of such a high proportion of elastin, there may be
a role for desmosine in pulmonary medicine. This can be diagnostic,to evaluate
therapy and its prognosis. To this date Investigations that have taken place,
could not give DES a role in daily practice.. This is partly due to the small
study populations that have been used and due to the complexity and costliness
of the laboratory assessment.
In recent years there is lots of advancement in this field. Mass spectrometry
(MS) combined with ultra-pressure liquid chromatography (UPLC), is one of the
most interesting develpments. With UP-MS/MS (iso) desmosine can be measured in
various body fluids. UP-MS/MS gives a good sensitivity and specificity in the
measurement of (iso) desmosine.
In the past mostly desmosine (DES) measurements took place in 24 hour urine.
UP-MS/MS allows accurate measurements in the serum. Correlation between 24-hour
urine DES and plasma DES has been examined in only a small subgroup. Inter-day
variation for 24 hour urine was considered relatively stable with a
coefficient of variation of about 8%. This is, however, for plasma DES.
Study objective
This study aims to determine the normal distribution of desmosine in a healthy
population and a population of patients with COPD (ranging from GOLD I-IV). In
addition, the inter-day variation and the correlation with 24-hour urinary
desmosine will be determined.
Study design
Cross sectional descriptive study
Study burden and risks
Hematoma caused by vena puncture in the arm.
Possible pulmonary function testing
Weg door Jonkerbos 100
6532 SZ Nijmegen
NL
Weg door Jonkerbos 100
6532 SZ Nijmegen
NL
Listed location countries
Age
Inclusion criteria
Control population: adult, mentally competent subjects without pulmonary disease
COPD population: adult, mentally competent patients. (The diagnosis was made **according to GOLD guidelines. ).
Exclusion criteria
Control population; pregnancy, pulmonary complaints
COPD population; reversibility in lung function (> 12% and 200ml), recent COPD exacerbation (<3 months before enrollment), pulmonary malignancy, lobectomie/pneumectomie, pregnancy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL37215.091.11 |